CTOs on the Move

Rimsys Regulatory Management Software

www.rimsys.io

 
Learn about the first and only holistic Regulatory Information Management (RIM) software for medical device companies that consolidates all the functions of regulatory affairs.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.rimsys.io
  • 100, South Commons
    Pittsburgh, PA USA 15212
  • Phone: 855.846.7269

Executives

Name Title Contact Details
Jeff Burk
Chief Technology Officer Profile

Similar Companies

Camber Pharmaceuticals Inc

Camber Pharmaceuticals Inc is a Piscataway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quality Care Solutions Inc

Quality Care Solutions Inc is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

WISDOM TRADITIONS COUNSELING SERVICES

Wisdom Traditions is an Integrative Healthcare Center located in Anchorage Alaska. Specializing in Mind/Body approaches, we offer a variety of services ranging from acupuncture, physical therapy and manual medicine to professional counseling, life c...

Marker Therapeutics

We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStartâ„¢ to improve the ability of the cellular immune system to recognize and destroy diseased cells.

Elabscience

Elabscience is a biotech corporation that specializes in laboratory reagents for life science research, including ELISA kits, FCM antibodies, biochemical kits, antibodies, and proteins.